174 related articles for article (PubMed ID: 15468100)
1. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease.
Morrish P
Mov Disord; 2005 Jan; 20(1):117; author reply 117-8. PubMed ID: 15468100
[No Abstract] [Full Text] [Related]
2. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
Pöpperl G; Tatsch K; Ruzicka E; Storch A; Gasser T; Schwarz J
J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
[TBL] [Abstract][Full Text] [Related]
3. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.
Tatsch K
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):711-4. PubMed ID: 11976813
[No Abstract] [Full Text] [Related]
4. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline.
Schwarz J; Storch A; Koch W; Pogarell O; Radau PE; Tatsch K
J Nucl Med; 2004 Oct; 45(10):1694-7. PubMed ID: 15471835
[TBL] [Abstract][Full Text] [Related]
5. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
[TBL] [Abstract][Full Text] [Related]
6. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
Frey KA
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814
[No Abstract] [Full Text] [Related]
7. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
8. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
Koch W; Radau PE; Hamann C; Tatsch K
J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
[TBL] [Abstract][Full Text] [Related]
9. Objective measures for the progression of Parkinson's disease.
Snow B
J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908
[No Abstract] [Full Text] [Related]
10. L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings.
Evans AH; Costa DC; Gacinovic S; Katzenschlager R; O'sullivan JD; Heales S; Lee P; Lees AJ
Mov Disord; 2004 Oct; 19(10):1232-6. PubMed ID: 15390012
[TBL] [Abstract][Full Text] [Related]
11. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease.
Geng Y; Shi GH; Jiang Y; Xu LX; Hu XY; Shao YQ
J Zhejiang Univ Sci B; 2005 Jan; 6(1):22-7. PubMed ID: 15593387
[TBL] [Abstract][Full Text] [Related]
12. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
[TBL] [Abstract][Full Text] [Related]
13. [Functional neuroimaging in movement disorders].
Borbély K
Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
[TBL] [Abstract][Full Text] [Related]
14. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
Brooks DJ; Frey KA; Marek KL; Oakes D; Paty D; Prentice R; Shults CW; Stoessl AJ
Exp Neurol; 2003 Nov; 184 Suppl 1():S68-79. PubMed ID: 14597329
[TBL] [Abstract][Full Text] [Related]
15. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
16. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.
Weintraub D; Newberg AB; Cary MS; Siderowf AD; Moberg PJ; Kleiner-Fisman G; Duda JE; Stern MB; Mozley D; Katz IR
J Nucl Med; 2005 Feb; 46(2):227-32. PubMed ID: 15695780
[TBL] [Abstract][Full Text] [Related]
17. [Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders].
Kanyó B; Argyelán M; Dibó G; Szakonyi Z; Vécsei L; Fülöp F; Láncz A; Forgács P; Pávics L
Ideggyogy Sz; 2003 Jul; 56(7-8):231-40. PubMed ID: 12971118
[TBL] [Abstract][Full Text] [Related]
18. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
[TBL] [Abstract][Full Text] [Related]
19. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
[TBL] [Abstract][Full Text] [Related]
20. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.
Marek K; Jennings D; Seibyl J
Adv Neurol; 2003; 91():183-91. PubMed ID: 12442677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
